The serotonin transporter in psychiatric disorders: insights from PET imaging
The DOI matches its Crossref record; 86 of the 89 references it cites were found in a registry or an index.
Abstract
Over the past 20 years, psychotropics affecting the serotonergic system have been used extensively in the treatment of psychiatric disorders. Molecular imaging, in particular PET, has allowed for elucidation of the essential contribution of the serotonin transporter to the pathophysiology of various psychiatric disorders and their treatment. We review studies that use PET to measure cerebral serotonin transporter activity in psychiatric disorders, focusing on major depressive disorder and antidepressant treatment. We also discuss opportunities and limitations in the application of this neuroimaging method in clinical practice. Although results from individual studies diverge, meta-analysis indicates a trend towards reduced serotonin transporter availability in patients with major depressive disorder. Inconsistencies in results might suggest symptom heterogeneity in major depressive disorder and might therefore be relevant for stratification of patients into clinical subsets. PET has enabled the elucidation of mechanisms of response to selective serotonin reuptake inhibitors (SSRIs) and hence provides a basis for rational pharmacological treatment of major depressive disorder. Such imaging studies have also suggested that the pattern of serotonin transporter binding before treatment might predict response to antidepressant treatment, which could potentially be clinically useful in the future. Additionally, this Review discusses PET studies investigating the serotonin transporter in anxiety, obsessive-compulsive disorder, and eating disorders. Few studies have shown changes in serotonin transporter activity in schizophrenia and attention deficit hyperactivity disorder. By showing the scarcity of data in these psychiatric disorders, we highlight the potential for further investigation in this field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although a relation between SERT occupancy and clinical improvement in depressive symptoms has not been shown [1]”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [1]
In the citing paper
“As one postulated working mechanism of many antidepressants is serotonin reuptake inhibition via blockade of SERT [1]”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [1]
In the citing paper
“There is no firm evidence that clinical efficacy [1, 17, 45], nor adverse effects are dependent on SERT occupancy; the studies included in the present review that measured the relationship between clinical effect and SERT occupancy did not find significant correlations [17, 32, 37, 38, 48].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [1]
In the citing paper
“comparison of occupancy data from different brain regions is potentially not meaningful, as SERT is not equally distributed throughout the brain [1].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [1]
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Hu, X.-Z., Lipsky, R. H., Zhu, G., Akhtar, L. A., Taubman, J., Greenberg, B. D., Xu, K., Arnold, P. D., Richter, M. A., Kennedy, J. L., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/503850 · Cited by 1,123
PET versus SPECT: strengths, limitations and challenges
Rahmim, A., & Zaidi, H. (2008) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e3282f3a515 · Cited by 834
Tryptophan depletion causes a rapid lowering of mood in normal males
Young, S. N., Smith, S. E., Pihl, R. O., & Ervin, F. R. (1985) · Psychopharmacology · doi:10.1007/bf00431803 · Cited by 713
Collier, D. A., Stöber, G., Li, T., Heils, A., Catalano, M., Bella, D. D., Arranz, M. J., Murray, R. M., Vallada, H., Bengel, D., et al. (1996) · PubMed · Cited by 665
The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants
Nakamura, M., Ueno, S., Sano, A., & Tanabe, H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000698 · Cited by 633
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Serotonin Uptake Sites and Serotonin Receptors Are Altered in the Limbic System of Schizophrenics
Joyce, J. N., Shane, A., Lexow, N., Winokur, A., Casanova, M. F., & Kleinman, J. E. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.32 · Cited by 340
Meyer, J. H., Wilson, A. A., Ginovart, N., Goulding, V., Hussey, D., Hood, K., & Houle, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1843 · Cited by 340
Benkelfat, C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950090019003 · Cited by 336
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
“PET was also used to characterize in vivo serotonin transporter (SERT or 5HTT) occupancy by serotonin reuptake inhibitors (SSRIs) [46, 69, 800, 801, 864, 1118 , 1165].”
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Self-citationMaillet, A., Krack, P., Lhommée, E., Météreau, E., Klinger, H., Favre, E., Le Bars, D., Schmitt, E., Bichon, A., Pelissier, P., et al. (2016) · Brain · doi:10.1093/brain/aww162 · Cited by 282
The Science Behind the Academy for Eating Disorders' Nine Truths About Eating Disorders
Schaumberg, K., Welch, E., Breithaupt, L., Hübel, C., Baker, J. H., Munn‐Chernoff, M. A., Yilmaz, Z., Ehrlich, S., Mustelin, L., Ghaderi, A., et al. (2017) · European Eating Disorders Review · doi:10.1002/erv.2553 · Cited by 266
Circuit Mechanisms of Reward, Anhedonia, and Depression
Höflich, A., Michenthaler, P., Kasper, S., & Lanzenberger, R. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy081 · Cited by 253
“…was further reported that the serotonergic transmitter system has a modulatory impact on the reward network via different receptors such as the 5-HT 1A , 5-HT 2A receptors, and the serotonin transporter (5-HTT) (Lanzenberger et al., 2012; Hahn et al., 2014; Kraus et al., 2014; Spies et al., 2015).”
BackgroundSelf-citation
Metadata
- Authors
- Spies, M., Knudsen, G. M., Lanzenberger, R., & Kasper, S.
- Affiliations
- Medical University of Vienna (AT)
- Rigshospitalet (DK)
- Corresponding author
- Kasper, Siegfried
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 2
- Issue
- 8
- Pages
- 743-755
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W1890188363
- Cited by
- 177
- References
- 89
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 8 · 2023: 13 · 2022: 13 · 2021: 41 · 2020: 13 · 2019: 13 · 2018: 11 · 2017: 22 · 2016: 17 · 2015: 4
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Novartis
- Eli Lilly and Company
- Deutsche Forschungsgemeinschaft
- AstraZeneca
- Bristol-Myers Squibb
- GlaxoSmithKline
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- serotonin transporter, positron emission tomography, major depressive disorder, antidepressant response, selective serotonin reuptake inhibitors, anxiety disorders, obsessive-compulsive disorder, eating disorders, schizophrenia, attention deficit hyperactivity disorder, mental illness, symptom heterogeneity, treatment response prediction
- MeSH terms
- Antidepressive Agents, Anxiety Disorders, Feeding and Eating Disorders, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Major, Humans, Obsessive-Compulsive Disorder, Schizophrenia, Tomography, Emission-Computed, Single-Photon, Selective Serotonin Reuptake Inhibitors, Attention Deficit and Disruptive Behavior Disorders, Serotonin Plasma Membrane Transport Proteins, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The serotonin transporter in psychiatric disorders: insights from PET imaging. https://app.cochat.ai/papers/10.1016/s2215-0366(15)00232-1
- The paper
- Spies, M., Knudsen, G. M., Lanzenberger, R., & Kasper, S. (2015). The serotonin transporter in psychiatric disorders: insights from PET imaging. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(15)00232-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.